Armata Pharmaceuticals (TG1N) Financial Statements
Armata Pharmaceuticals Financial Overview
Armata Pharmaceuticals's market cap is currently $109.20M. The company's EPS TTM is $-5.30; its P/E ratio is -0.62; Armata Pharmaceuticals is estimated to report earnings on November 18, 2026, and the estimated EPS forecast is $-0.50. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 4.90M | $ 5.17M | $ 4.53M | $ 5.51M | $ 4.47M |
| Gross Profit | $ 3.37M | $ -29.25M | $ 3.56M | $ -29.51M | $ -15.54M |
| Operating Income | $ -31.22M | $ -42.44M | $ -40.89M | $ -36.95M | $ -23.82M |
| EBITDA | $ -155.68M | $ -6.85M | $ -65.45M | $ -36.00M | $ -21.92M |
| Net Income | $ -173.80M | $ -18.92M | $ -69.05M | $ -36.92M | $ -23.16M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 8.69M | $ 9.29M | $ 13.52M | $ 14.85M | $ 10.29M |
| Total Assets | $ 76.88M | $ 86.44M | $ 98.36M | $ 107.88M | $ 69.77M |
| Total Debt | $ 288.02M | $ 126.52M | $ 120.37M | $ 48.81M | $ 37.99M |
| Net Debt | $ 279.33M | $ 117.22M | $ 106.85M | $ 33.96M | $ 27.70M |
| Total Liabilities | $ 295.48M | $ 134.46M | $ 130.43M | $ 71.80M | $ 44.37M |
| Stockholders' Equity | $ -218.60M | $ -48.02M | $ -32.06M | $ 36.08M | $ 25.40M |
| Cash Flow | |||||
| Free Cash Flow | $ -26.30M | $ -39.43M | $ -55.57M | $ -34.69M | $ -24.88M |
| Operating Cash Flow | $ -25.76M | $ -37.55M | $ -47.42M | $ -32.48M | $ -23.57M |
| Investing Cash Flow | $ -542.00K | $ -1.88M | $ -8.13M | $ -2.21M | $ -1.30M |
| Financing Cash Flow | $ 25.61M | $ 34.96M | $ 53.99M | $ 44.02M | $ 25.52M |
Currency in USD
